Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer

Journal of Surgical Oncology

Volumn 103, Issue 1, 2011, Pages 62-68

  Fujiwara, Hitoshi ^a   Suchi, Kentaro ^a   Okamura, Shinichi ^a   Okamura, Hiroko ^a   Umehara, Seiji ^a   Todo, Momoko ^a   Shiozaki, Atsushi ^a   Kubota, Takeshi ^a   Ichikawa, Daisuke ^a   Okamoto, Kazuma ^a   Ochiai, Toshiya ^a   Kokuba, Yukihito ^a   Sonoyama, Teruhisa ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

chemoradiation response; CRP; esophageal squamous cell carcinoma; IL 6

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; FLUOROURACIL; INTERLEUKIN 6;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER SIZE; CANCER TISSUE; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

AGED; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650666975     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21751     Document Type: Article

References (29)

1. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-234.
2. Nozoe T, Saeki H, Sugimachi K,: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
3. Ikeda M, Natsugoe S, Ueno S, et al.: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003; 238: 197-202.
4. Shimada H, Nabeya Y, Okazumi S, et al.: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-252. (Pubitemid 36936011)
5. Crumley AB, McMillan DC, McKernan M, et al.: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006; 94: 1568-1571.
6. Castell JV, Gomez-Lechon MJ, David M, et al.: Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186.
7. Wang LS, Chow KC, Wu CW,: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999; 80: 1617-1622.
8. Oka M, Yamamoto K, Takahashi M, et al.: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996; 56: 2776-2780.
9. Deans DA, Wigmore SJ, Gilmour H, et al.: Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006; 95: 1568-1575.
10. Sobin LH, Witedkind CH,: UICC TNM classification of malignant tumors, 5th edition. New York: Wiley-Liss, Inc.; 1997; pp 66-69.
11. Roxburgh CS, McMillan DC,: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-163.
12. Kobayashi T, Teruya M, Kishiki T, et al.: Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery 2008; 144: 729-735.
13. Guillem P, Triboulet JP,: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005; 18: 146-150.
14. Oka M, Iizuka N, Yamamoto K, et al.: The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 1001-1006.
15. Leu CM, Wong FH, Chang C, et al.: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003; 22: 7809-7818.
16. Borsellino N, Bonavida B, Ciliberto G, et al.: Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999; 85: 134-144.
17. Mizutani Y, Bonavida B, Koishihara Y, et al.: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995; 55: 590-596.
18. Wang Y, Niu XL, Qu Y, et al.: Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010; 295: 110-123.
19. Wei LH, Kuo ML, Chen CA, et al.: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001; 20: 5799-5809.
20. Chen CC, Chen WC, Lu CH, et al.: Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010; 76: 1214-1224.
21. Miyamoto Y, Hosotani R, Doi R, et al.: Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res 2001; 21: 2449-2456.
22. Balkwill F, Mantovani A,: Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-545.
23. Izzo JG, Malhotra U, Wu TT, et al.: Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24: 748-754.
24. Izzo JG, Wu X, Wu TT, et al.: Therapy-induced expression of NF-κB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 2009; 22: 127-132.
25. Mantovani A, Allavena P, Sica A, et al.: Cancer-related inflammation. Nature 2008; 454: 436-444.
26. Karin M,: Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
27. Chen Z, Malhotra PS, Thomas GR, et al.: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-1379.
28. Allen C, Duffy S, Teknos T, et al.: Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13: 3182-3190.
29. Ren Y, Cao B, Law S, et al.: Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: A prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005; 11: 6190-6197.